Gritstone bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Gritstone bio şirketinin toplam hissedar öz sermayesi $22.2M ve toplam borcu $40.5M olup, bu da borç-öz sermaye oranını 182.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $142.5M ve $120.4M dir.

Anahtar bilgiler

182.5%

Borç/özkaynak oranı

US$40.51m

Borç

Faiz karşılama oranı	n/a
Nakit	US$55.71m
Eşitlik	US$22.19m
Toplam yükümlülükler	US$120.35m
Toplam varlıklar	US$142.54m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2JQ 'nin kısa vadeli varlıkları ( $60.7M ) kısa vadeli yükümlülüklerini ( $23.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: 2JQ 'un kısa vadeli varlıkları ( $60.7M ) uzun vadeli yükümlülüklerini ( $96.5M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2JQ şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 2JQ şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 182.5% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 2JQ şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 2JQ un, serbest nakit akışı her yıl % 13.8 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Gritstone bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

Recent updates

Gritstone bio, Inc. Announces Encouraging Updated Interim Phase 2 Data from Ongoing Phase 2 Study Evaluating GRANITE

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index

New major risk - Revenue and earnings growth

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

New major risk - Market cap size

New major risk - Share price stability

Gritstone Bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.31 loss in 2Q 2023)

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Full year 2023 earnings released: US$1.20 loss per share (vs US$1.32 loss in FY 2022)

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.35 loss in 3Q 2022)

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2022)

New major risk - Financial position

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.34 loss in 1Q 2022)

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$1.32 loss per share (vs US$0.95 loss in FY 2021)

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Third quarter 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in 3Q 2021)

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 2Q 2021)

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.16 profit in 1Q 2021)

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

Less than half of directors are independent

Gritstone Bio, Inc. Announces Positive Clinical Results from First Cohort of A Phase 1 Study (CORAL-BOOST) Evaluating A T Cell-Enhanced Self-Amplifying mRNA (SamRNA) Vaccine Against COVID-19

Gritstone bio, Inc Announces Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.69 loss in 3Q 2020)

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

Gritstone Bio, Inc. Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.69 loss in 2Q 2020)

High number of new directors

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Growth Index

First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020)

Full year 2020 earnings released: US$2.79 loss per share (vs US$2.81 loss in FY 2019)

Revenue beats expectations

Gritstone Oncology, Inc. Announces Promotions Within its Leadership Team

Gritstone Oncology, Inc Announces Board Appointments

Executive VP & CTO recently sold €182k worth of stock

Gritstone Oncology, Inc. and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

Gritstone Oncology, Inc. Advances Development of Second Generation Vaccine Against SARS-CoV-2

Gritstone Oncology, Inc. announced that it expects to receive $15.000001 million in funding

New 90-day high: €3.34

Gritstone Oncology, Inc. announced that it expects to receive $110 million in funding from Avidity Partners Management LP, EcoR1 Capital, LLC, Redmile Group, LLC, and other investors

Gritstone Oncology, Inc Announces Resignation of Jean-Marc Bellemin as Chief Financial Officer

New 90-day high: €2.82

Third quarter 2020 earnings released: US$0.69 loss per share

Revenue misses expectations

Gritstone Oncology, Inc. Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE

Gritstone Oncology, Inc.(NasdaqGS:GRTS) dropped from S&P Global BMI Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço